ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology ...

Abbott Laboratories will report earnings pre-market on January 22, with an earnings consensus of $1.04 per share. See why I ...

Here is how Abbott (ABT) and Acurx Pharmaceuticals, Inc. (ACXP) have performed compared to their sector so far this year.

With recent advances in technology, we are being introduced to the world of real-time support managing chronic diseases via ...

International Assets Investment Management LLC reduced its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 99.1% during the 4th quarter, Holdings Channel reports. The fund owned 14,721 shares ...

Abbott Laboratories (NYSE:ABT – Free Report) had its price objective boosted by Evercore ISI to $136.00 in a report released on Thursday morning,Stock Target Advisor reports. They currently have a buy ...

North Chicago-based Abbott announced last month it reached a settlement agreement with Dexcom over all outstanding patent disputes relating to their glucose monitoring products, which estimate blood ...

In a report released on January 6, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

In our view, the biggest risks Abbott faces include ongoing difficulties with its left ventricular assist devices, and the potential commercial success of its Libre franchise, which includes planned ...

Abbott is trading at a forward 12-month price-to-sales (P/S) multiple of 4.4X, a 22% discount to the Zacks Medical Products ...

If you have $1,000 to invest right now -- or even less -- here are two no-brainer healthcare players that make a great ...